Download PDF
Fortschr Neurol Psychiatr 2011; 79(2): 83-91
DOI: 10.1055/s-0029-1245937
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Die Relevanz einer B-Zell-abhängigen Immunpathologie für die Multiple Sklerose

The Significance of a B Cell-Dependent Immunopathology in Multiple SclerosisS. Kuerten1 , R. Pauly1 , S. Blaschke1 , A. Rottlaender1 , C. C. Kaiser2 , M. Schroeter2 , G. R. Fink2 , K. Addicks1
  • 1Anatomie I, Universität zu Köln
  • 2Klinik und Poliklinik für Neurologie, Universitätsklinikum Köln
Further Information

Publication History

Publication Date:
20 January 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Immunpathologie der Multiplen Sklerose (MS) ist bis heute nicht vollständig verstanden. Im Mittelpunkt der vorliegenden Arbeit stehen die B-Lymphozyten, die als Produzenten von Autoantikörpern und durch die Fähigkeit zur Präsentation von Antigenen eine Schlüsselstellung einnehmen können, jedoch bislang in ihrer Bedeutung für die MS unterschätzt wurden. Auch wird die Bildung von ektopen B-Zell-Follikeln im ZNS und deren mögliche Korrelation mit dem Krankheitsverlauf und Schweregrad diskutiert. Nicht zuletzt sollen regulatorische Aspekte einer B-Zell-abhängigen Pathologie erwähnt werden. Ein umfassendes Verständnis der komplexen Immunprozesse der MS kann Therapien hervorbringen, die spezifisch in die Pathogenese eingreifen. Ansatzpunkte einer B-Zell-orientierten Therapie werden im Folgenden erörtert. Insgesamt soll dieser Übersichtsartikel dazu anstoßen, bestehende Paradigmen der Erkrankung zu überdenken und die Rolle der B-Lymphozyten bei der MS zu würdigen.

Abstract

In spite of keen clinical and neuroscientific interest, the aetiology and immunopathology of multiple sclerosis (MS) remain to be elucidated. The present work seeks to give insight into the important, but thus far underestimated contribution of B cells to the disease. Emphasis will be placed on the role of B cells as producers of autoantibodies and as antigen presenting cells. In addition, the development of ectopic B cell follicles in the CNS and their potential correlation with the course of the disease and MS severity will be discussed. Finally, regulatory functions of a B cell-dependent immunopathology should be mentioned. A better understanding of the complex pathomechanisms of MS will allow for therapeutic options that are causative. Potential targets of a B cell-oriented therapy will be delineated in the following review. We hereby aim at triggering a critical re-evaluation of traditional paradigms assigned to MS, appreciating the importance of B cells in the disease.

Schlüsselwörter

Antikörper - Autoimmunität - B-Lymphozyten - EAE - MS

Keywords

antibodies - autoimmunity - B cells - EAE - MS

Literatur

  • 1 Batoulis H, Addicks K, Kuerten S. Emerging concepts in autoimmune encephalomyelitis beyond the CD 4 /T(H)1 paradigm.  Ann Anat. 2010;  192 179-193
    Google Scholar
  • 2 Lassmann H, Ransohoff R M. The CD 4-Th1 model for multiple sclerosis: a critical re-appraisal.  Trends Immunol. 2004;  25 132-137
    Google Scholar
  • 3 Awad A, Hemmer B, Hartung H P et al. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis.  J Neuroimmunol. 2010;  219 1-7
    Google Scholar
  • 4 Luque F A, Jaffe S L. Cerebrospinal fluid analysis in multiple sclerosis.  Int Rev Neurobiol. 2007;  79 341-56
    Google Scholar
  • 5 Sospedra M, Martin R. Immunology of multiple sclerosis.  Annu Rev Immunol. 2005;  23 683-747
    Google Scholar
  • 6 Franciotta D, Salvetti M, Lolli F et al. B cells and multiple sclerosis.  Lancet Neurol. 2008;  7 852-858
    Google Scholar
  • 7 Bielekova B, Becker B. Monoclonal antibodies in MS – Mechanisms of action.  Neurology. 2010;  74 (Suppl 1) S31-S40
    Google Scholar
  • 8 Owens G P, Bennett J L, Lassmann H et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid.  Ann Neurol. 2009;  65 639-649
    Google Scholar
  • 9 Reindl M, Linington C, Brehm U et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.  Brain. 1999;  122 2047-2056
    Google Scholar
  • 10 Reindl M, Khalil M, Berger T. Antibodies as biological markers for pathophysiological processes in MS.  J Neuroimmunol. 2006;  180 50-62
    Google Scholar
  • 11 Büdingen H C, Harrer M D, Kuenzle von S et al. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies.  Eur J Immunol. 2008;  38 2014-2023
    Google Scholar
  • 12 Büdingen H C, Gulati von M, Kuenzle S et al. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce „oligoclonal bands”.  J Neuroimmunol. 2010;  218 134-139
    Google Scholar
  • 13 Magliozzi R, Howell O, Vora A et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.  Brain. 2007;  130 1089-1104
    Google Scholar
  • 14 Keegan M, König F, McClelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.  Lancet. 2005;  366 579-582
    Google Scholar
  • 15 Hauser S L, Waubant E, Arnold D L et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.  N Engl J Med. 2008;  358 676-688
    Google Scholar
  • 16 Schröder A, Ellrichmann G, Chehab G et al. Einsatz von Rituximab in der Behandlung neuroimmunologischer Erkrankungen.  Nervenarzt. 2009;  80 155-165
    Google Scholar
  • 17 Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update.  Expert Rev Neurother. 2010;  10 791-809
    Google Scholar
  • 18 Rivers T M, Schwentker F F. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys.  J Exp Med. 1935;  61 689-702
    Google Scholar
  • 19 Kabat E A, Moore D H, Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and the relationship to the serum proteins.  J Clin Invest. 1942;  21 571-577
    Google Scholar
  • 20 Link H, Baig S, Jiang Y P et al. B cells and antibodies in MS.  Res Immunol. 1989;  140 219-226
    Google Scholar
  • 21 Bernard C C, Rosbo N K. Immunopathological recognition of autoantigens in multiple sclerosis.  Acta Neurol. 1991;  13 171-178
    Google Scholar
  • 22 Menon de K, Piddlesden S J, Bernard C C. Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin.  J Neurochem. 1997;  69 214-222
    Google Scholar
  • 23 Van der Goes A, Kortekaas M, Hoekstra K et al. The role of anti-myelin (auto)-antibodies in the phagocytosis of myelin by macrophages.  J Neuroimmunol. 1999;  101 61-67
    Google Scholar
  • 24 Ponomarenko N A, Durova O M, Vorobiev I I et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen.  Proc Natl Acad Sci U S A. 2006;  103 281-286
    Google Scholar
  • 25 Karthigasan J, Garvey J S, Ramamurthy G V et al. Immunolocalization of 17 and 21.5 kDa MBP isoforms in compact myelin and radial component.  J Neurocytol. 1996;  25 1-7
    Google Scholar
  • 26 Wucherpfennig K W. Autoimmunity in the central nervous system: mechanisms of antigen presentation and recognition.  Clin Immunol Immunopathol. 1994;  72 293-306
    Google Scholar
  • 27 Yamamoto Y, Yoshikawa H, Nagano S et al. Myelin-associated oligodendrocytic basic protein is essential for normal arrangement of the radial component in central nervous system myelin.  Eur J Neurosci. 1998;  11 847-855
    Google Scholar
  • 28 Lehmann P V, Forsthuber T, Miller A et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen.  Nature. 1992;  358 155-157
    Google Scholar
  • 29 Popot J L, Pham Dinh D, Dautigny A. Major Myelin proteolipid: the 4-alpha-helix topology.  J Membr Biol. 1991;  120 233-246
    Google Scholar
  • 30 Schliess F, Stoffel W. Evolution of the myelin integral membrane proteins of the central nervous system.  Biol Chem Hoppe Seyler. 1991;  372 865-874
    Google Scholar
  • 31 Tumani H, Hartung H P, Hemmer B et al. Cerebrospinal fluid biomarkers in multiple sclerosis.  Neurobiol Dis. 2009;  35 117-127
    Google Scholar
  • 32 Ehling R, Lutterotti A, Wanschitz J et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis.  Mult Scler. 2004;  10 601-606
    Google Scholar
  • 33 Silber E, Semra Y K, Gregson N A et al. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.  Neurology. 2002;  58 1372-1381
    Google Scholar
  • 34 Sadatipour B T, Greer J M, Pender M P. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis.  Ann Neurol. 1998;  44 980-983
    Google Scholar
  • 35 Banki K, Colombo E, Sia F et al. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis.  J Exp Med. 1994;  180 1649-1663
    Google Scholar
  • 36 Mathey E K, Derfuss T, Storch M K et al. Neurofascin as novel target for antibody mediated axonal injury.  J Exp Med. 2007;  204 2363-2372
    Google Scholar
  • 37 Menge T, Lalive P H, Budingen H C et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis.  J Allergy Clin Immunol. 2005;  116 453-459
    Google Scholar
  • 38 Villar L M, Sadaba M C, Roldan von E et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.  J Clin Invest. 2005;  115 187-194
    Google Scholar
  • 39 Silber E, Semra Y K, Gregson N A et al. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.  Neurology. 2002;  58 1372-1381
    Google Scholar
  • 40 Eikelenboom M J, Petzold A, Lazeron R H et al. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.  Neurology. 2003;  60 219-223
    Google Scholar
  • 41 Sidén A. Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS.  J Neurol. 1979;  221 39-51
    Google Scholar
  • 42 Link H, Huang Y M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness.  J Neuroimmunol. 2007;  180 17-28
    Google Scholar
  • 43 Vaheri A, Keski-Oja J, Salonen E M et al. Cerebrospinal fluid IgG bands and virus-specific IgG, IgM, and IgA antibodies in herpes simplex virus encephalitis.  J Neuroimmunol. 1982;  3 247-261
    Google Scholar
  • 44 Stanek G. Laboratory diagnosis and seroepidemiology of Lyme borreliosis.  Infection. 1991;  19 263-267
    Google Scholar
  • 45 Ceroni M, Camana C, Franciotta D M et al. Specific activation of B-cell clones within the central nervous system in course of herpes simplex encephalitis.  Boll Soc Ital Biol Sper. 1990;  66 1223-1230
    Google Scholar
  • 46 Shen X, Tan Y. Detection of oligoclonal immunoglobulins in the cerebrospinal fluid by immunofixation electrophoresis.  Clin Chem Lab Med. 2001;  39 1209-1210
    Google Scholar
  • 47 Dornmair K, Meinl E, Hohlfeld R. Novel approaches for identifying target antigens of autoreactive human B and T cells.  Semin Immunopathol. 2009;  31 467-477
    Google Scholar
  • 48 Lucchinetti C, Brück W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.  Ann Neurol. 2000;  47 707-717
    Google Scholar
  • 49 Qin Y, Duquette P, Zhang Y et al. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis.  Lab Invest. 2003;  83 1081-1088
    Google Scholar
  • 50 Rock K L, Benacerraf B, Abbas A K. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors.  J Exp Med. 1984;  160 1102-1113
    Google Scholar
  • 51 Constant S L. B lymphocytes as antigen-presenting cells for CD 4þ T cell priming in vivo.  J Immunol. 1999;  162 5695-5703
    Google Scholar
  • 52 Greter M, Heppner F L, Lemos M P et al. Dendritic cells permit immune invasion of the CNS in animal model of multiple sclerosis.  Nat Med. 2005;  11 328-334
    Google Scholar
  • 53 Racke M. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies.  Curr Opin Neurol. 2008;  21 (Suppl 1) S9-S18
    Google Scholar
  • 54 Harp C T, Lovett-Racke A E, Racke M K et al. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis.  Clin Immunol. 2008;  128 382-391
    Google Scholar
  • 55 Serafini B, Rosicarelli B, Magliozzi R et al. Detection of ectopic B-cell follicles with germinal centers in meninges of patients with secondary progressive multiple sclerosis.  Brain Pathol. 2004;  14 164-174
    Google Scholar
  • 56 Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases.  Nat Rev Immunol. 2006;  6 205-217
    Google Scholar
  • 57 Kaiser C C, Shukla D K, Stebbins G T et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.  J Neuroimmunol. 2009;  211 124-130
    Google Scholar
  • 58 Serafini B, Severa M, Columba-Cabezas S et al. Epstein-Barr virus latent i nfection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation.  J Neuropathol Exp Neurol. 2010;  69 677-693
    Google Scholar
  • 59 Bø L, Vedeler C A, Nyland H et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration.  Mult Scler. 2003;  9 323-331
    Google Scholar
  • 60 Willis S N, Stadelmann C, Rodig S J et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.  Brain. 2009;  132 3318-3328
    Google Scholar
  • 61 Sargsyan S A, Shearer A J, Ritchie A M et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis.  Neurology. 2010;  74 1127-1135
    Google Scholar
  • 62 Fillatreau S, Sweenie C H, McGeachy M J et al. B cells regulate autoimmunity by provision of IL-10.  Nat Immunol. 2002;  3 944-950
    Google Scholar
  • 63 Matsushita T, Yanaba K, Bouaziz J D et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.  J Clin Invest. 2008;  118 3420-3430
    Google Scholar
  • 64 Warrington A E, Asakura K, Bieber A J et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis.  Proc Natl Acad Sci USA. 2000;  97 6820-6825
    Google Scholar
  • 65 Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.  Brain. 2006;  129 1953-1971
    Google Scholar
  • 66 Goverman J, Brabb T. Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis.  Lab Anim Sci. 1996;  46 482-492
    Google Scholar
  • 67 Kuerten S, Angelov D N. Comparing the CNS morphology and immunobiology of different EAE models in C 57BL/ 6 mice – a step towards understanding the complexity of multiple sclerosis.  Ann Anat. 2008;  190 1-15
    Google Scholar
  • 68 Steinmann L, Zamvil S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.  Trends in Immunol. 2005;  26 565-571
    Google Scholar
  • 69 Steinman L, Zamvil S S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis.  Ann Neurol. 2006;  60 12-21
    Google Scholar
  • 70 Yip H C, Karulin A Y, Tary-Lehmann M et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response.  J Immunol. 1999;  162 3942-3949
    Google Scholar
  • 71 Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis.  Ann Neurol. 2005;  58 939-945
    Google Scholar
  • 72 Stefferl A, Storch M K, Linington C et al. Disease progression in chronic relapsing experimental allergic encephalomyelitis is associated with reduced inflammation-driven production of corticosterone.  Endocrinology. 2001;  142 3616-3612
    Google Scholar
  • 73 Genain C P, Nguyen M H, Letvin N L et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.  J Clin Invest. 1995;  96 2966-2974
    Google Scholar
  • 74 't Hart B A, Massacesi L. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus).  J Neuropathol Exp Neurol. 2009;  68 341-355
    Google Scholar
  • 75 Hjelmstrom P, Juedes A E, Fjell J et al. B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization.  J Immunol. 1998;  161 4480-4483
    Google Scholar
  • 76 Oliver A R, Lyon G M, Ruddle N H. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C 57BL/ 6 mice.  J Immunol. 2003;  171 462-468
    Google Scholar
  • 77 Kuerten S, Lichtenegger F S, Faas S et al. MBP-PLP fusion protein-induced EAE in C 57BL/ 6 mice.  J Neuroimmunol. 2006;  177 99-111
    Google Scholar
  • 78 Kuerten S, Javeri S, Tary-Lehmann M et al. Fundamental differences in the CNS lesion development and composition in MP 4- and MOG:35 – 55-induced EAE.  Clin Immunol. 2008;  129 256-267
    Google Scholar
  • 79 Elliott E A, McFarland H I, Nye S H et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.  J Clin Invest. 1996;  98 1602-1612
    Google Scholar
  • 80 Pöllinger B, Krishnamoorthy G, Berer K et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.  J Exp Med. 2009;  206 1303-1316
    Google Scholar
  • 81 Genc K, Dona D L, Reder A T. Increased CD 80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.  J Clin Invest. 1997;  99 2664-2671
    Google Scholar
  • 82 Kim H J, Ifergan I, Antel J P et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.  J Immunol. 2004;  172 7144-7153
    Google Scholar
  • 83 Kala M, Rhodes S N, Piao W H et al. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.  Exp Neurol. 2010;  221 136-145
    Google Scholar
  • 84 Begum-Haque S, Sharma A, Christy M et al. Increased expression of B-cell associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis.  J Neuroimmunol. 2010;  219 47-53
    Google Scholar
  • 85 Krumbholz M, Faber H, Steinmeyer F et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.  Brain. 2008;  131 1455-1463
    Google Scholar
  • 86 Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.  Nat Rev Drug Discov. 2005;  4 510-518
    Google Scholar
  • 87 Rudick R A, Sandrock A. Natalizumab. alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.  Expert Rev Neurother. 2004;  4 571-580
    Google Scholar
  • 88 Krumbholz M, Meinl I, Kümpfel T et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.  Neurology. 2008;  71 1350-1354
    Google Scholar
  • 89 Weissert R. Progressive multifocal leukoencephalopathy.  J Neuroimmunol. 2010;  [Epub ahead of print]
    Google Scholar
  • 90 Meinl E, Krumbholz M, Hohlfeld R. B linage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production and therapeutic modulation.  Ann Neurol. 2006;  59 880-892
    Google Scholar
  • 91 Menge T, Büdingen H C, Dalakas M C et al. B-Zell-gerichtete Multiple-Sklerose-Therapie: Aktueller Stand.  Nervenarzt. 2009;  80 190-198
    Google Scholar
  • 92 Cross A H, Stark J L, Lauber J et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.  J Neuroimmunol. 2006;  180 63-70
    Google Scholar
  • 93 Nückel H, Frey U H, Röth A et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.  Eur J Pharmacol. 2005;  514 217-224
    Google Scholar
  • 94 Hawker K. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data.  Curr Opin Neurol. 2008;  21 (Suppl 1) S19-S25
    Google Scholar
  • 95 Monson N. The natural history of B cells.  Curr Opin Neurol. 2008;  21 (Suppl 1) S3-S8
    Google Scholar
  • 96 Chan A, Weilbach F X, Toyka K V et al. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.  Clin Exp Immunol. 2005;  139 152-158
    Google Scholar

Dr. Stefanie Kuerten

Anatomie I, Universität zu Köln

Joseph-Stelzmann-Str. 9

50931 Köln

Email: stefanie.kuerten@uk-koeln.de